A non-randomized, single-center phase II study of bevacizumab in combination with etoposide plus cisplatin in patients with extended-stage small cell lung cancer (SCLC), who have not received prior chemotherapy.
Phase of Trial: Phase II
Latest Information Update: 11 Jun 2010
At a glance
- Drugs Bevacizumab; Cisplatin; Etoposide
- Indications Small cell lung cancer
- Focus Adverse reactions
- Sponsors Roche
- 11 Jun 2010 Status changed from not yet recruiting to discontinued as reported by Roche record.
- 22 Apr 2010 New trial record